Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Liposomal Targeted Delivery Overcomes Immunostimulatory Effects of Oligonucleotide Based Therapy In Chronic Lymphocytic Leukemia.

Bo Yu, Yicheng Mao, Li-Yuan Bai, Sarah E.M. Herman, Asha Ramanunni, Yan Jin, Xiaokui Mo, PhD, Carolyn Cheney, Kenneth K. Chan, PhD, David Jarjoura, Guido Marcucci, MD, Robert Lee, L.James Lee, John C. Byrd, MD, Natarajan Muthusamy, DVM, PhD

Blood (2010) 116 (21): 1475.

https://doi.org/10.1182/blood.V116.21.1475.1475

Published: 2010

Journal Articles

The Mll PTD and Flt3 ITD Double Knock-In Mouse Develops Acute Leukemia and Recapitulates Phenotypic, Molecular and Epigenetic Characteristics of the Counterpart Human Acute Myeloid Leukemia

Nicholas Zorko, Susan P. Whitman, PhD, Kelsie Bernot, PhD, Myntee T. Ngangana, Ronald Siebenaler, Shujun Liu, Ph.D., Yue-Zhong Wu, MS, Chidimma Kalu, Xiaoli Zhang, PhD, MS, David Jarjoura, PhD, Zhiliang Xie, MD, Kenneth K. Chan, PhD, Adrienne M. Dorrance, PhD, Benjamin H. Lee, MD, PhD, Roger Briesewitz, PhD, Danilo Perrotti, MD, PhD, Guido Marcucci, MD, Michael A. Caligiuri, MD

Blood (2010) 116 (21): 150.

https://doi.org/10.1182/blood.V116.21.150.150

Published: 2010

Journal Articles

Tetrahydrouridine Co-Administration Improves Oral Bioavailability and Dampens Inter-Individual Variability of Decitabine Pharmacokinetics In Baboons

Donald Lavelle, Ph.D., Kestis Vaitkus, YongHua Ling, Nicola Smith, Kenneth K. Chan, PhD, Joseph DeSimone, PhD, Yogenthiran Saunthararajah, MD

Blood (2010) 116 (21): 2081.

https://doi.org/10.1182/blood.V116.21.2081.2081

Published: 2010

Journal Articles

Evidence of MicroRNA-29b and Sp1/NFκB-HDAC Regulatory Network for KIT Expression in KIT-Driven Acute Myeloid Leukemia (AML): Biologic and Therapeutic Implications.

Shujun Liu, PhD, Lai Chu Wu, PhD, Jiuxia Pang, BS, Ramasamy Santhanam, PhD, Sebastian Schwind, MD, Yue-Zhong Wu, MS, Christopher Hickey, MS, Jianhua Yu, PhD, Anjali Mishra, PhD, Heiko Becker, MD, Chenglong Li, PhD, Roger Briesewitz, PhD, Robert A. Baiocchi, MD, Kenneth K. Chan, PhD, Michael A. Caligiuri, MD, John C. Byrd, MD, Danilo Perrotti, MD, PhD, Ramiro Garzon, MD, Guido Marcucci, MD

Blood (2009) 114 (22): 938.

https://doi.org/10.1182/blood.V114.22.938.938

Published: 2009

Journal Articles

Preliminary Results of a Phase II Study of Low Dose Decitabine as a Single Agent in Older Patients (age≥60) with Previously Untreated Acute Myeloid Leukemia (AML)

William Blum, MD, Rebecca Klisovic, MD, Shujun Liu, PhD, Ramiro Garzon, MD, Cheryl Kefauver, RN, Zhongfa Liu, PhD, Jon Mickle, CNP, Hollie Devine, CNP, Steve Devine, MD, Michael R Grever, MD, Kenneth K Chan, PhD, Miguel Villalona-Calero, MD, John C. Byrd, MD, Guido Marcucci, MD

Blood (2008) 112 (11): 2957.

https://doi.org/10.1182/blood.V112.11.2957.2957

Published: 2008

Journal Articles

Phase I Study of Low Dose Decitabine in Patients with Acute Myeloid Leukemia (AML): Pharmacokinetics (PK), Pharmacodynamics (PD), and Clinical Activity.

William Blum, MD, Rebecca Bruner-Klisovic, MD, Shujun Liu, PhD, John C. Byrd, MD, Zhongfa Liu, PhD, Kenneth K. Chan, PhD, Cheryl Kefauver, R.N., Lenguyen Huynh, Michael R. Grever, MD, Guido Marcucci, MD

Blood (2005) 106 (11): 1861.

https://doi.org/10.1182/blood.V106.11.1861.1861

Published: 2005

Journal Articles

Efficacy and Safety of the Combination of Genasense™ (Oblimersen Sodium, Bcl-2 Antisense Oligonucleotide), Fludarabine and Rituximab in Previously Treated and Untreated Subjects with Chronic Lymphocytic Leukemia.

Blanche Mavromatis, MD, Kanti R. Rai, MD, Paul K. Wallace, PhD, Claudia Soho, OCN, Beverly Landrigan, RN, Patricia Meyn, RN, Tracey Wei, MS, Kenneth K. Chan, PhD, Philomena Casey, MS, Steven C. Novick, MD, PhD, Asher A. Chanan-Khan, MD

Blood (2005) 106 (11): 2129.

https://doi.org/10.1182/blood.V106.11.2129.2129

Published: 2005

NARROW

Liposomal Targeted Delivery Overcomes Immunostimulatory Effects of Oligonucleotide Based Therapy In Chronic Lymphocytic Leukemia.

The Mll PTD and Flt3 ITD Double Knock-In Mouse Develops Acute Leukemia and Recapitulates Phenotypic, Molecular and Epigenetic Characteristics of the Counterpart Human Acute Myeloid Leukemia

Tetrahydrouridine Co-Administration Improves Oral Bioavailability and Dampens Inter-Individual Variability of Decitabine Pharmacokinetics In Baboons

Evidence of MicroRNA-29b and Sp1/NFκB-HDAC Regulatory Network for KIT Expression in KIT-Driven Acute Myeloid Leukemia (AML): Biologic and Therapeutic Implications.

Preliminary Results of a Phase II Study of Low Dose Decitabine as a Single Agent in Older Patients (age≥60) with Previously Untreated Acute Myeloid Leukemia (AML)

Phase I Study of Low Dose Decitabine in Patients with Acute Myeloid Leukemia (AML): Pharmacokinetics (PK), Pharmacodynamics (PD), and Clinical Activity.

Efficacy and Safety of the Combination of Genasense™ (Oblimersen Sodium, Bcl-2 Antisense Oligonucleotide), Fludarabine and Rituximab in Previously Treated and Untreated Subjects with Chronic Lymphocytic Leukemia.

Email alerts

ASH Publications

American Society of Hematology

Liposomal Targeted Delivery Overcomes Immunostimulatory Effects of Oligonucleotide Based Therapy In Chronic Lymphocytic Leukemia.

The Mll PTD and Flt3 ITD Double Knock-In Mouse Develops Acute Leukemia and Recapitulates Phenotypic, Molecular and Epigenetic Characteristics of the Counterpart Human Acute Myeloid Leukemia

Tetrahydrouridine Co-Administration Improves Oral Bioavailability and Dampens Inter-Individual Variability of Decitabine Pharmacokinetics In Baboons

Evidence of MicroRNA-29b and Sp1/NFκB-HDAC Regulatory Network for KIT Expression in KIT-Driven Acute Myeloid Leukemia (AML): Biologic and Therapeutic Implications.

Preliminary Results of a Phase II Study of Low Dose Decitabine as a Single Agent in Older Patients (age≥60) with Previously Untreated Acute Myeloid Leukemia (AML)

Phase I Study of Low Dose Decitabine in Patients with Acute Myeloid Leukemia (AML): Pharmacokinetics (PK), Pharmacodynamics (PD), and Clinical Activity.

Efficacy and Safety of the Combination of Genasense™ (Oblimersen Sodium, Bcl-2 Antisense Oligonucleotide), Fludarabine and Rituximab in Previously Treated and Untreated Subjects with Chronic Lymphocytic Leukemia.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only